Table 4 Evaluation of variables related to therapy discontinuation at the time of the switch from oETA to bETA.

From: Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis

Variables

Odds ratio

95% CI

p-value

Age

1.185

0.864–1.871

0.093

Gender (M vs F)

0.968

0.598–1.312

0.623

Disease Duration

0.965

0.516–0.133

0.231

Concomitant Therapy

0.996

0.898–1.864

0.213

Duration of oETA treatment (months)

0.879

0.522–1.467

0.676

1.042

0.783–1.925

0.426

0.898

0.601–1.142

0.545

1.070

0.671–1.507

0.823

  1. Disease activity has been assessed with DAS28 for RA patients, DAPSA for PsA and BASDAI for AS on each follow-up visit; there were no missing data.
  2. RA rheumatoid arthritis, PsA psoriatic arthritis, AS ankylosing spondylitis, DAS28 Disease Activity Score 28, DAPSA Disease Activity in Psoriatic Arthritis, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, oETA etanercept originator, bETA etanercept biosimilar, CI confidence interval.
Back to article page